口服碳酸氢钠对CKD骨转换标志物的影响:BASE先导试验二次分析
该研究为BASE先导试验的事后分析,纳入194例总CO2 20-28 mEq/L的CKD患者,随机接受安慰剂或两种剂量碳酸氢钠治疗28周。结果显示碳酸氢钠呈剂量依赖性升高血清可溶性klotho水平,但对iFGF-23、iPTH、B-SAP等其他骨代谢标志物无显著影响。
要点
- 碳酸氢钠剂量依赖性升高血清可溶性klotho水平。
- 对iFGF-23、iPTH、B-SAP等骨转换标志物无显著影响。
- 基线总CO2<24与≥24 mEq/L者骨标志物变化相似。
核心结论
- 在总CO2 20-28 mEq/L的CKD患者中,碳酸氢钠治疗28周升高血清klotho水平,但未影响其他骨健康标志物。
研究设计与样本
- BASE先导试验(NCT02521181)的事后分析,194例CKD患者随机分配至安慰剂或碳酸氢钠0.5或0.8 mEq/kg瘦体重/天,治疗28周。
主要发现
- 与安慰剂相比,碳酸氢钠呈剂量依赖性增加血清可溶性klotho水平。
- 两种剂量碳酸氢钠对iFGF-23、iPTH、B-SAP等其他骨生物标志物均无显著影响。
- 基线总CO2<24 mEq/L与≥24 mEq/L亚组间骨标志物变化相似。
关键数值与推荐
- 血清总CO2范围20-28 mEq/L;碳酸氢钠剂量0.5或0.8 mEq/kg瘦体重/天;治疗28周。
临床怎么用
- 对于总CO2 20-28 mEq/L的CKD患者,碳酸氢钠可能升高klotho,但未显示改善骨转换标志物,临床决策需结合其他证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SIGNIFICANCE STATEMENT: In CKD, metabolic acidosis is commonly treated with alkali in the hope that it will improve bone health. In a post hoc analysis of the Bicarbonate Administration to Stabilize eGFR Pilot Trial, we investigated whether sodium bicarbonate affects serum levels of bone turnover markers and other hormones related to bone health in individuals with CKD who have normal to slightly reduced total CO2 (20-28 mEq/L). Sodium bicarbonate increased serum levels of α-klotho but had no significant effect on other bone health markers, including intact fibroblast growth factor-23 (iFGF-23), intact parathyroid hormone (iPTH), and bone-specific alkaline phosphatase (B-SAP). Further study is needed to determine the effect of bicarbonate administration on clinical aspects of bone health. BACKGROUND: Treatment with alkali has been hypothesized to improve bone health in CKD by mitigating adverse effects of acid on bone mineral. We investigated the effect of treatment with sodium bicarbonate on bone turnover markers and other factors related to bone metabolism in CKD. METHODS: This is a post hoc analysis of the Bicarbonate Administration to Stabilize eGFR Pilot Trial in which 194 individuals with CKD and serum total CO2 20-28 mEq/L were randomly assigned to placebo or one of two doses of sodium bicarbonate (0.5 or 0.8 mEq/kg lean body weight per day) for 28 weeks. The following serum measurements were performed at baseline, week 12, and week 28: B-SAP, c-telopeptide, procollagen type I intact N-terminal propeptide, iPTH, iFGF-23, soluble klotho, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and tartrate-resistant acid phosphatase 5b. The difference (sodium bicarbonate versus placebo) in mean change of each bone biomarker from baseline was determined using linear mixed models. RESULTS: One hundred sixty-eight participants submitted samples for post hoc investigations. Mean eGFR was 37±10 ml/min per 1.73 m2 and mean total CO2 was 24±3 mEq/L at baseline. Sodium bicarbonate induced a dose-dependent increase in soluble klotho levels compared with placebo. There was no significant effect of treatment with either dose of sodium bicarbonate on any of the other bone biomarkers, including iFGF-23, iPTH, and B-SAP. Effects on bone biomarkers were similar in those with baseline serum total CO2 <24 mEq/L compared with those with total CO2 ≥24 mEq/L. CONCLUSIONS: In this pilot trial of individuals with CKD and total CO2 20-28 mEq/L, sodium bicarbonate treatment increased serum klotho levels but did not affect other bone health markers over 28 weeks. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT02521181.
引用
- Raphael KL, Katz R, Larive B, et al. Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial. J Am Soc Nephrol. 2023. PMID: 38170601. doi:10.1681/ASN.0000000000000264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。